To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
Wim Parys
Strategic Advisor to the R&D Committee
Wim Parys served as the Chief Medical Officer of argenx from 2019 until 2022, when he transitioned to an advisory role to the Board. He has over 25 years of experience leading successful clinical programs in biopharma, including the development and regulatory submission of seven now-approved drugs.
Prior to argenx, he was the R&D Head of the newly established Global Public Health group at Janssen (Johnson & Johnson) responsible for a portfolio including programs in HIV (developing first long-acting therapy), TB, dengue fever, and malaria. Before this, Wim was the Head of Development of the Infectious Disease Therapeutic Area of Janssen and Tibotec, where he developed and launched innovative drugs for HIV (Prezista™, Intelence™, and Edurant™), Hepatitis C (Incivo™, Olysio™/Sovriad™), and TB (Sirturo™).
He started his career within the Johnson & Johnson organization at the Janssen Research Foundation in Belgium, where he led the R&D team developing galantamine (Reminyl™/Razadyne™) for Alzheimer’s disease. He obtained his medical degree from the Katholieke Universiteit in Leuven, Belgium and worked in private practice for nine years prior to joining industry.
|
Nationality |
Belgium |
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
Grants
Funding research, education, and initiatives that raise the standard of care.
About Us
Discover why we’re more than a unique name.
Newsroom
The latest news and press releases from argenx.
